23 completed. 23 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 23 |
| Phase 2 | 5 | Completed 5 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery selinexor, Correlative studies - Recurrent Melanoma | Phase 1 | Completed | Kari Kendra | 8 | 2014-08-22 | 2023-04-04 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-11-14 | 2023-12-22 |
| Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS) - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 17 | 2012-11-09 | 2025-05-16 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma cyclophosphamide, aldesleukin, autologous tumor cell vaccine - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 12 | 2012-03-01 | 2014-04-21 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Cisplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2010-08-01 | 2019-11-18 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
| Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma CD40 agonist monoclonal antibody CP-870,893, tremelimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 25 | 2010-02-01 | 2020-04-07 |
| Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, cyclophosphamide, biopsy - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2009-02-01 | 2017-04-19 |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2007-09-01 | 2017-02-15 |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma cyclophosphamide, therapeutic autologous lymphocytes, aldesleukin - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 11 | 2006-12-01 | 2012-03-16 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma sorafenib tosylate, temsirolimus - Melanoma, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 69 | 2006-04-01 | 2014-04-10 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery recombinant interferon alfa-2b, amifostine/azacitidine - Recurrent Melanoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2005-07-01 | 2013-05-03 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-06-05 |
| Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors bryostatin 1, temsirolimus - Recurrent Melanoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-05-03 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study - Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2004-07-01 | 2013-04-10 |
Showing 20 of 23. Sign in to see all of them.
Melanoma (23) · Carcinoma, Renal Cell (8) · Breast Neoplasms (5) · Astrocytoma (3) · Brain Neoplasms (3) · Breast Neoplasms, Male (3) · Colonic Neoplasms (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Medullary (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Glioblastoma (2) · Glioma (2)
Neoplasms (23) · Neoplasms by Histologic Type (23) · Neoplasms by Site (23) · Neoplasms, Germ Cell and Embryonal (23) · Neoplasms, Nerve Tissue (23) · Neuroectodermal Tumors (23) · Nevi and Melanomas (23) · Skin Diseases (23) · Skin Neoplasms (23) · Skin and Connective Tissue Diseases (23) · Neuroendocrine Tumors (22) · Neoplasms, Glandular and Epithelial (11) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Male Urogenital Diseases (10)
Cyclophosphamide (4) · Immunohistochemistry (4) · Interleukin-2 (4) · Polymerase Chain Reaction (4) · aldesleukin (4) · Biopsy (3) · Ipilimumab (3) · Sirolimus (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · CTLA-4 Antigen (2) · Immunologic Techniques (2) · temsirolimus (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · Amifostine (1)
National Cancer Institute (NCI) (13) · Fred Hutchinson Cancer Center (3) · Abramson Cancer Center at Penn Medicine (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Kari Kendra (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Wake Forest University Health Sciences (1)
United States (22) · Canada (4)
Cassian Yee (2) · Aude Chapuis (1) · Crystal L Mackall (1) · David Solit (1) · Gary Hudes (1) · Jeffrey Weber (1) · Julian R. Molina, M.D., Ph.D. (1) · Kari Kendra (1) · Keith Flaherty (1) · Kevin Kim (1) · Kunle Odunsi (1) · Lisa McGregor (1) · Mario Sznol (1) · Mark Dickson (1) · Meredith K Chuk (1)
PMID 27269940, PMID 28816150, PMID 31401903, PMID 32192573, PMID 39863139, PMID 40132910
K12CA076930 (2), U01CA062505 (2), U01CA069856 (2), U01CA132123 (2), UM1CA097452 (2), N01CM62202 (1), N01CM62206 (1), P30CA008748 (1), P30CA012197 (1), P30CA016056 (1), P30CA016672 (1), R01CA158318 (1), R21CA099265 (1), R21CA128283 (1), U01CA069912 (1)